Semaglutide + Glycine.
Compounded semaglutide formulated with glycine for stability and tolerability.
1 / 2 / 4 / 6 / 10 mg semaglutide with 0.5 mg glycine per mL · subcutaneous injectablePricing is shown after your free assessment, before you commit.
Free to start. No card required.
Reviewed by Lumora clinical team (Licensed provider network)Mixed evidenceSource: Client-approved product catalog; provider review required
Evidence, regulatory status, and fit vary by medication, formulation, route, and individual history.
Is this for you?
This is for you if
- Patients on semaglutide therapy who do not tolerate B12 or prefer not to use it
- Patients sensitive to cobalt or cobalamin
- Patients pursuing precise physician-guided titration across multiple concentration tiers
This isn't for you if
All safety information for semaglutide applies — see the Semaglutide product page.
Semaglutide + Glycine
This formulation combines compounded semaglutide with glycine — a small amino acid used in compounded formulations to support solution stability and pH buffering. Glycine has independent research interest in sleep, glucose handling, and protein synthesis.
Mechanism and fit.
The semaglutide acts on GLP-1 receptors exactly as the standalone formulation does. Glycine supports formulation stability and may offer modest independent benefits for sleep and metabolic balance. Patients who do not tolerate B12-paired formulations often do well with the glycine version.
Who this is typically for.
- Patients on semaglutide therapy who do not tolerate B12 or prefer not to use it
- Patients sensitive to cobalt or cobalamin
- Patients pursuing precise physician-guided titration across multiple concentration tiers
What patients
most often ask.
Why would I choose glycine over B12?
Patients sensitive to B-vitamin formulations, or those with very high baseline B12, often prefer the glycine version. The two have effectively identical semaglutide content; the cofactor differs.
Who this is typically for.
These are common fit patterns from the approved catalog. Your provider determines whether treatment is appropriate.
- <ul><li>Patients on semaglutide therapy who do not tolerate B12 or prefer not to use it</li><li>Patients sensitive to cobalt or cobalamin</li><li>Patients pursuing precise physician-guided titration across multiple concentration tiers</li></ul>
How this option
is evaluated.
The plan is provider-determined after reviewing your assessment and safety factors.
- DosingWeekly subcutaneous injection, titrated by your provider.
- Typical durationLong-term, individualized based on response and labs.
- Safety and eligibilityYour provider reviews contraindications, medication interactions, goals, and safety factors before prescribing.
- A licensed provider reviews your assessment before any treatment is recommended.
- You see full pricing - visit fees, medication, labs, follow-up - before you commit.
- Your plan can be adjusted, paused, or stopped based on response and safety. Your clinician is reachable - not a chatbot.
- Compounded medications are not FDA-approved and are dispensed only when prescribed by a licensed provider.
Start with
provider review.
If you are considering Semaglutide + Glycine, the first step is a free assessment. A provider determines whether it fits your goals and medical history.
A provider determines whether treatment is clinically appropriate.